98%
921
2 minutes
20
The p53 Y220C mutation is frequently observed in human cancers. This mutation renders the p53 Y220C unstable at physiological temperatures, leading to a loss of its normal function and promoting tumor development. In this study, a total of eight compounds were designed and synthesized based on the active compound C8. The protein thermal shift assay revealed that both C8-3b and C8-6 exhibited similar activity of C8, with a ΔT value of +0.5 °C. Compounds C8-1a, C8-1b, and C8-2b were found to enhance the thermostability of p53 Y220C (ΔT: + 1.0 °C), the melting temperature exhibits an enhancement of 0.5 °C over the C8, indicating that these compounds possess the ability to stabilize p53 Y220C. The results of the cell viability assay revealed that C8-1b exhibited selective inhibitory effects on the proliferation of tumor cells harboring the p53 Y220C mutation. Furthermore, we utilized molecular docking and two-dimensional interaction analysis to elucidate the binding mode and key interactions of these compounds with p53 Y220C. Our study suggests that these compounds could potentially serve as lead compounds for enhancing the stability of p53 Y220C, thus providing a rational approach for designing small molecule stabilizers against p53 mutations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bmcl.2025.130161 | DOI Listing |
Invest New Drugs
August 2025
Department of Biochemical and Molecular Medical Sciences, College of Science and Engineering, National Dong Hwa University, Hualien, 974301, Taiwan, R.O.C..
Ovarian cancer remains one of the most lethal gynecologic malignancies, largely due to high recurrence rates and treatment-related toxicities. Although PARP inhibitors like Olaparib have shown efficacy in BRCA-mutated cancers, their benefit is limited in broader patient populations. TP53 mutations, highly prevalent in ovarian cancer, promote tumor progression and resistance, making p53 a key therapeutic target.
View Article and Find Full Text PDFInt J Mol Sci
July 2025
Department of Computer Science, Wesleyan University, Middletown, CT 06457, USA.
Network theory analysis has emerged as a powerful approach for investigating the complex behavior of dynamic and interactive systems, including proteomic systems. One key application of these methods is the study of long-range signaling dynamics in proteins, a phenomenon known as allostery. In this study, we applied computational models using network theory analysis to explore long-range electrostatic interactions and allosteric drug rescue mechanisms in the DNA-binding domain (DBD) of the p53 protein, a critical tumor suppressor whose dysfunction, often caused by missense mutations, is implicated in over 50% of human cancers.
View Article and Find Full Text PDFCell Death Differ
July 2025
The Simons Center for Systems Biology, Institute for Advanced Study, Princeton, NJ, USA.
Rezatapopt is an investigational small molecule p53 reactivator that binds specifically to the Y220C-mutant p53 protein without interacting with wild-type or other mutant p53 proteins. Upon binding, rezatapopt stabilizes the Y220C-mutant p53 protein in the wild-type conformation, reactivating p53 functions. The Phase 1 PYNNACLE trial assessed rezatapopt in solid tumors.
View Article and Find Full Text PDFInt J Mol Sci
July 2025
Hematopoietic and Leukemic Development Team, Centre de Recherche Saint-Antoine, 75012 Paris, France.
is the most frequently mutated gene in human cancers. Many studies have reported oncogenic gain of function by mutant p53 and suggested that mutant p53 is a potential therapeutic target. In striking contrast, a recent approach relying on CRISPR-mediated mutagenesis led to the conclusion that mutant p53 removal in tumors had no therapeutic value.
View Article and Find Full Text PDFBlood
July 2025
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States.
TP53-Y220C is a recurrent hotspot mutation in cancers and leukemias. It is observed predominantly in acute myeloid leukemia (AML)/myelodysplastic syndromes among hematological malignancies and is associated with poor outcome. The mutation creates a structural pocket in the p53 protein.
View Article and Find Full Text PDF